Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916061 | 0.88 | CHRNB2 (0.43) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 | |
| SCHEMBL1393583 | 0.80 | MAPT (0.49) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 | |
| SCHEMBL30630187 | 0.79 | CHRNB2 (0.47) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 | |
| SCHEMBL25895983 | 0.78 | MAPT (0.50) | MAPTRAB9A | |
| SCHEMBL25894890 | 0.78 | MAPT (0.50) | MAPTRAB9A | |
| SCHEMBL17796627 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 | |
| SCHEMBL162438 | 0.76 | CHRNB2 (0.45) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 | |
| SCHEMBL29742016 | 0.76 | CHRNB2 (0.45) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 | |
| SCHEMBL24177527 | 0.75 | CHRNB2 (0.42) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 | |
| SCHEMBL2722889 | 0.75 | MAPT (0.58) | CHRNB2CHRNA4MAPTCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| US-12129262-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-10-29 | — | — | US | disclosed |
| US-20220267345-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267345-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CHRNB2 4594/4885CHRNA4 4647/4885MAPT 1795/4885 |
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CHRNB2 4594/4885CHRNA4 4647/4885MAPT 1795/4885 |
| US-12129262-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CHRNB2 4594/4885CHRNA4 4647/4885MAPT 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.